Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients

INTRODUCTION: Carboplatin (CBDCA) administered at a dosage of 4 mg/mL/min or more area under the blood concentration-time curve (AUC) is considered to be ranked as the highest chemotherapy-induced nausea and vomiting (CINV) risk of the moderately emetogenic chemotherapy agents. The complete response...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMJ Open
Autori principali: Iihara, Hirotoshi, Shimokawa, Mototsugu, Abe, Masakazu, Hayasaki, Yoh, Fujita, Yukiyoshi, Nagasawa, Yuki, Sakurai, Michiru, Matsuoka, Rie, Suzuki, Akio, Morishige, Kenichiro
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2019
Soggetti:
Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6340435/
https://ncbi.nlm.nih.gov/pubmed/30782732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-024357
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi